<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Palliative care: pain management with opioids; Morphine: palliative care; Morphine: palliative care: breakthrough pain; Pain: palliative care: breakthrough; Palliative care: breakthrough pain; Oxycodone: palliative care; Analgesics: opioid: equivalent doses; Morphine: palliative care: codeine equivalence; Morphine: palliative care: diamorphine equivalence; Morphine: palliative care: dihydrocodeine equivalence; Morphine: palliative care: hydromorphone equivalence; Morphine: palliative care: morphine equivalence; Morphine: palliative care: oxycodone equivalence; Morphine: palliative care: tramadol equivalence; Codeine: palliative care: morphine equivalence; Diamorphine: palliative care: morphine equivalence; Dihydrocodeine: palliative care, morphine equivalence; Hydromorphone: palliative care: morphine equivalence; Oxycodone: palliative care: morphine equivalence; Tramadol: palliative care: morphine equivalence; Diamorphine: palliative care; Morphine: palliative care; Fentanyl: palliative care: transdermal route; Buprenorphine: palliative care: transdermal route; Buprenorphine: palliative care: morphine equivalence; Morphine: palliative care: buprenorphine equivalence; Fentanyl: palliative care: morphine equivalence; Morphine: palliative care: fentanyl equivalence" /><meta name="IX" content="Palliative care: pain management with opioids; Morphine: palliative care; Morphine: palliative care: breakthrough pain; Pain: palliative care: breakthrough; Palliative care: breakthrough pain; Oxycodone: palliative care; Analgesics: opioid: equivalent doses; Morphine: palliative care: codeine equivalence; Morphine: palliative care: diamorphine equivalence; Morphine: palliative care: dihydrocodeine equivalence; Morphine: palliative care: hydromorphone equivalence; Morphine: palliative care: morphine equivalence; Morphine: palliative care: oxycodone equivalence; Morphine: palliative care: tramadol equivalence; Codeine: palliative care: morphine equivalence; Diamorphine: palliative care: morphine equivalence; Dihydrocodeine: palliative care, morphine equivalence; Hydromorphone: palliative care: morphine equivalence; Oxycodone: palliative care: morphine equivalence; Tramadol: palliative care: morphine equivalence; Diamorphine: palliative care; Morphine: palliative care; Fentanyl: palliative care: transdermal route; Buprenorphine: palliative care: transdermal route; Buprenorphine: palliative care: morphine equivalence; Morphine: palliative care: buprenorphine equivalence; Fentanyl: palliative care: morphine equivalence; Morphine: palliative care: fentanyl equivalence" /><title>Pain management with opioids: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP18865-pain-management-with-opioids.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP18865-pain-management-with-opioids.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP18865-pain-management-with-opioids.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 12 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP59-guidance-on-prescribing.htm">Guidance on prescribing</a> &gt; <a href="PHP113-prescribing-in-palliative-care.htm">Prescribing in palliative care</a> &gt; <a href="PHP18864-pain.htm">Pain </a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP18864-pain.htm" title="Previous: Pain">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP120-symptom-control.htm" title="Next: Symptom control">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Pain management with opioids</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><div><h2><span></span><span></span>Oral route</h2><p>Treatment with morphine is given by mouth as immediate-release or modified-release preparations. During the titration phase the initial dose is based on the previous medication used, the severity of the pain, and other factors such as presence of renal impairment, increasing age, or frailty. Recommended starting doses vary but, generally, a starting dose between 20–30 mg daily is safe for opioid-naïve patients and 40–60 mg daily for patients being switched from a regular weak opioid. The dose is given either as an immediate-release preparation 4-hourly or as a modified-release preparation 12-hourly, in addition to rescue doses.</p><p>If pain occurs between regular doses of morphine (‘breakthrough pain’), an additional dose (‘rescue dose’) of immediate-release morphine should be given. An additional dose should also be given 30 minutes before an activity that causes pain, such as wound dressing. The standard dose of a strong opioid for breakthrough pain is usually one-tenth to one-sixth of the regular 24-hour dose, repeated every 2–4 hours as required (up to hourly may be needed if pain is severe or in the last days of life). Review pain management if rescue analgesic is required frequently (twice daily or more). Each patient should be assessed on an individual basis. Formulations of fentanyl that are administered nasally, buccally or sublingually are also licensed for breakthrough pain.</p></div><p>When adjusting the dose of morphine, the number of rescue doses required and the response to them should be taken into account; increments of morphine should not exceed one-third to one-half of the total daily dose every 24 hours. Thereafter, the dose should be adjusted with careful assessment of the pain, and the use of adjuvant analgesics should also be considered. Upward titration of the dose of morphine stops when either the pain is relieved or unacceptable adverse effects occur, after which it is necessary to consider alternative measures.</p><p>Morphine immediate-release 30 mg 4-hourly (or modified-release 100 mg 12-hourly) is usually adequate for most patients; some patients require morphine immediate-release up to 200 mg 4-hourly (or modified-release 600 mg 12-hourly), occasionally more is needed.</p><p>Once their pain is controlled, patients started on 4-hourly immediate-release morphine can be transferred to the same total 24-hour dose of morphine given as the modified-release preparation for 12-hourly or 24-hourly administration. The first dose of the modified-release preparation is given with, or within 4 hours of, the last dose of the immediate-release preparation. For preparations suitable for 12-hourly or 24-hourly administration see modified-release preparations under <a title="MORPHINE SALTS" href="PHP2740-morphine-salts.htm">Morphine</a>. Increments should be made to the dose, not to the frequency of administration. The patient must be monitored closely for efficacy and side-effects, particularly constipation, and nausea and vomiting. A suitable <a title="1.6 Laxatives" href="PHP546-laxatives.htm">laxative</a>  should be prescribed routinely.</p><p id="PHP18924"><a title="OXYCODONE HYDROCHLORIDE" href="PHP2766-oxycodone-hydrochloride.htm">Oxycodone</a> can be used in patients who require an opioid but cannot tolerate morphine. If the patient is already receiving an opioid, oxycodone should be started at a dose equivalent to the current analgesic (see below). Oxycodone immediate-release preparations can be given for breakthrough pain.</p><p> </p><div class="table"><div class="cAA">Equivalent doses of opioid analgesics</div><table class="table" summary="Equivalent doses of opioid analgesics" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; border-left: 1pt solid ; border-right: 1pt solid ; "><colgroup><col /><col /><col /></colgroup><thead><tr style="border-bottom: 1pt solid ; "><th style="border-bottom: 1pt solid ; " colspan="3">This is only an <strong>approximate</strong> guide (doses may not correspond with those given in clinical practice); patients should be carefully monitored after any change in medication and dose titration may be required</th></tr></thead><tbody style="vertical-align: top;"><tr style=""><td style="vertical-align: middle;"><strong>Analgesic</strong></td><td style="vertical-align: middle;"><strong>Route</strong></td><td style="vertical-align: middle;"><strong>Dose</strong></td></tr><tr><td style="">Codeine</td><td style="">PO</td><td style="">100 mg</td></tr><tr><td style="">Diamorphine</td><td style="">IM, IV, SC</td><td style="">3 mg</td></tr><tr><td style="">Dihydrocodeine</td><td style="">PO</td><td style="">100 mg</td></tr><tr><td style="">Hydromorphone</td><td style="">PO</td><td style="">2 mg</td></tr><tr><td style="">Morphine</td><td style="">PO</td><td style="">10 mg</td></tr><tr><td style="">Morphine</td><td style="">IM, IV, SC</td><td style="">5 mg</td></tr><tr><td style="">Oxycodone</td><td style="">PO</td><td style="">6.6 mg</td></tr><tr style="border-bottom: 1pt solid ; "><td style="border-bottom: 1pt solid ; ">Tramadol</td><td style="border-bottom: 1pt solid ; ">PO</td><td style="border-bottom: 1pt solid ; ">100 mg</td></tr><tr><td style="text-align: left;" colspan="3">PO = by mouth; IM = intramuscular, IV = intravenous, SC = subcutaneous</td></tr></tbody></table></div><div><h2>Parenteral route</h2><p>The equivalent parenteral dose of morphine (subcutaneous, intramuscular, or intravenous) is about half of the oral dose. If the patient becomes unable to swallow, generally morphine is administered as a continuous subcutaneous infusion (for details, see<a title="Subcutaneous continuous infusion administration" href="PHP130-continuous-subcutaneous-infusions.htm"> Continuous Subcutaneous Infusions</a>  ). Diamorphine  is sometimes preferred, because being more soluble, it can be given in a smaller volume. The equivalent subcutaneous dose of diamorphine is about one-third of the oral dose of morphine.</p><p>If the patient can resume taking medicines by mouth, then oral morphine may be substituted for subcutaneous infusion of morphine or diamorphine, see table above of approximate equivalent doses of morphine and diamorphine. The infusion is discontinued when the first oral dose of morphine is given.</p></div><div><h2>Rectal route</h2><p>Morphine is also available for rectal administration as suppositories; alternatively oxycodone suppositories can be obtained on special order.</p></div><div><h2>Transdermal route</h2><p id="PHP18923">Transdermal preparations of fentanyl and buprenorphine are available <a title="4.7.2 Opioid analgesics" href="PHP2667-opioid-analgesics.htm">(section 4.7.2</a> ); they are not suitable for acute pain or in patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Prescribers should ensure that they are familiar with the correct use of transdermal preparations, see under <a title="BUPRENORPHINE" href="PHP2680-buprenorphine.htm">buprenorphine</a>  and <a title="FENTANYL" href="PHP2713-fentanyl.htm">fentanyl</a>  (inappropriate use has caused fatalities). Immediate-release morphine can be given for breakthrough pain.</p><p>The following 24-hour oral doses of morphine are considered to be <em>approximately</em> equivalent to the buprenorphine and fentanyl patches shown, however when switching due to possible opioid-induced hyperalgesia, reduce the calculated equivalent dose of the new opioid by one-quarter to one-half. </p><div class="table"><div class="cAA">Buprenorphine patches are <strong><em>approximately</em></strong> equivalent to the following 24-hour doses of oral morphine</div><table class="table" summary="Buprenorphine patches are approximately equivalent to the following 24-hour doses of oral morphine" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; border-left: 1pt solid ; border-right: 1pt solid ; "><colgroup><col /><col /><col /><col /></colgroup><tbody><tr><td style="">morphine salt 12 mg daily</td><td style="">≡</td><td style=""><em>BuTrans</em><em>®</em> ‘5’ patch</td><td style="">7-day patches</td></tr><tr><td style="">morphine salt 24 mg daily</td><td style="">≡</td><td style=""><em>BuTrans®</em> ‘10’ patch</td><td style="">7-day patches</td></tr><tr style="border-bottom: 1pt solid ; "><td style="border-bottom: 1pt solid ; ">morphine salt 48 mg daily</td><td style="border-bottom: 1pt solid ; ">≡</td><td style="border-bottom: 1pt solid ; "><em>BuTrans®</em> ‘20’ patch</td><td style="border-bottom: 1pt solid ; ">7-day patches</td></tr><tr><td style="">morphine salt 84 mg daily</td><td style="">≡</td><td style=""><em>Transtec®</em> ‘35’ patch</td><td style="">4-day patches</td></tr><tr><td style="">morphine salt 126 mg daily</td><td style="">≡</td><td style=""><em>Transtec®</em> ‘52.5’ patch</td><td style="">4-day patches</td></tr><tr style="border-bottom: 1pt solid ; "><td style="border-bottom: 1pt solid ; ">morphine salt 168 mg daily</td><td style="border-bottom: 1pt solid ; ">≡</td><td style="border-bottom: 1pt solid ; "><em>Transtec®</em> ‘70’ patch</td><td style="border-bottom: 1pt solid ; ">4-day patches</td></tr><tr><td style="" colspan="4"><div class="cG"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">Conversion ratios vary and these figures are a guide only. Morphine equivalences for transdermal opioid preparations have been approximated to allow comparison with available preparations of oral morphine</p></div></div></td></tr></tbody></table></div></div><div class="table"><div class="cAA">72-hour Fentanyl patches are <strong><em>approximately</em></strong> equivalent to the following 24-hour doses of oral morphine  </div><table class="table" summary="72-hour Fentanyl patches are approximately equivalent to the following 24-hour doses of oral morphine  " cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; border-left: 1pt solid ; border-right: 1pt solid ; "><colgroup><col /><col /><col /></colgroup><tbody><tr><td style="">morphine salt 30 mg daily</td><td style="">≡</td><td style="">fentanyl ‘12’ patch</td></tr><tr><td style="">morphine salt 60 mg daily </td><td style="">≡</td><td style="">fentanyl ‘25’ patch</td></tr><tr><td style="">morphine salt 120 mg daily </td><td style="">≡</td><td style="">fentanyl ‘50’ patch</td></tr><tr><td style="">morphine salt 180 mg daily</td><td style="">≡</td><td style="">fentanyl ‘75’ patch</td></tr><tr style="border-bottom: 1pt solid ; "><td style="border-bottom: 1pt solid ; ">morphine salt 240 mg daily</td><td style="border-bottom: 1pt solid ; ">≡</td><td style="border-bottom: 1pt solid ; ">fentanyl ‘100’ patch</td></tr><tr><td style="" colspan="3"><div class="cG"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">Conversion ratios vary and these figures are a guide only. Morphine equivalences for transdermal opioid preparations have been approximated to allow comparison with available preparations of oral morphine</p></div></div></td></tr></tbody></table></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP18864-pain.htm">Previous: Pain </a> | <a class="top" href="PHP18865-pain-management-with-opioids.htm#">Top</a> | <a accesskey="]" href="PHP120-symptom-control.htm">Next: Symptom control </a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>